(Reuters) – The U.S. Food and Drug Administration approved a treatment developed by AstraZeneca Plc and Merck & Co Inc for a rare genetic disorder, the companies said on Tuesday.
Koselugo has been approved for treating paediatric patients two years of age and older with a form of neurofibromatosis, which is a debilitating genetic condition that affects one in every 3,000 to 4,000 individuals.
(Reporting by Aakash Jagadeesh Babu in Bengaluru; Editing by Krishna Chandra Eluri)
Falcons vs Chiefs: Building a +1500 Same Game Parlay for Sunday Night Football
Flyers vs Capitals: What to expect in Philly’s preseason opener
Kai Wagner close to history as he equalizes Le Toux’s record
Flyers’ training facility continues to be among the NHL’s best
Jets fans swap superstitions for stories at NYC watch party
Mets owner Steve Cohen unveils renderings of Citi Field casino and park proposal in Queens
Washington Heights tenants of ‘NYC’s worst landlord’ are fed up and cleaning up
Another raid: Police Commissioner Thomas Donlon has homes searched by feds one week after being appointed top cop
Who are NYC street vendors? First-ever survey aims to answer that question, and highlight the challenges they face
Man in Bronx shot dead outside restaurant: cops
Councilmember Bottcher wants to require NYC gun stores to display graphic images as health warning
AEW star Adam Copeland talks injury, Pure Plank, and his future in wrestling
Inside the new IKEA Sleepeasy, made to help New Yorkers sleep more soundly
Health Department to spray parts of Manhattan and Brooklyn for disease-carrying mosquitoes next week
